Empire Valuation
Is C15 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of C15 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: C15 (€28) is trading below our estimate of fair value (€39.54)
Significantly Below Fair Value: C15 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for C15?
Key metric: As C15 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is C15's PE Ratio? | |
|---|---|
| PE Ratio | 14.5x |
| Earnings | CA$672.00m |
| Market Cap | CA$9.78b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.6x |
| Enterprise Value/EBITDA | 9.9x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does C15's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 23.6x | ||
HAW Hawesko Holding | 19.6x | 19.4% | €203.9m |
MSH WASGAU Produktions & Handels | 13.5x | n/a | €59.4m |
SBRY J Sainsbury | 43x | 21.5% | UK£5.9b |
KESKOB Kesko Oyj | 18.3x | 10.4% | €7.6b |
C15 Empire | 14.5x | n/a | €9.8b |
Price-To-Earnings vs Peers: C15 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the peer average (23.6x).
Price to Earnings Ratio vs Industry
How does C15's PE Ratio compare vs other companies in the European Consumer Retailing Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: C15 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the European Consumer Retailing industry average (14.8x).
Price to Earnings Ratio vs Fair Ratio
What is C15's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 14.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate C15's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €28.00 | €29.73 +6.2% | 5.9% | €31.75 | €25.67 | n/a | 8 |
| Nov ’25 | €26.00 | €28.91 +11.2% | 5.9% | €31.23 | €25.25 | n/a | 8 |
| Oct ’25 | €27.40 | €28.37 +3.5% | 10.0% | €31.22 | €21.92 | n/a | 7 |
| Sep ’25 | €25.20 | €25.65 +1.8% | 8.0% | €28.03 | €22.03 | n/a | 7 |
| Aug ’25 | €24.20 | €26.14 +8.0% | 7.6% | €27.99 | €22.53 | n/a | 7 |
| Jul ’25 | €23.60 | €26.14 +10.8% | 7.6% | €27.99 | €22.53 | n/a | 7 |
| Jun ’25 | €21.20 | €25.45 +20.0% | 7.9% | €28.34 | €22.27 | n/a | 7 |
| May ’25 | €21.80 | €25.69 +17.9% | 7.5% | €28.78 | €22.61 | n/a | 8 |
| Apr ’25 | €22.40 | €25.66 +14.5% | 7.9% | €29.23 | €22.43 | n/a | 8 |
| Mar ’25 | €23.20 | €27.18 +17.2% | 10.1% | €33.40 | €23.18 | n/a | 8 |
| Feb ’25 | €23.80 | €27.72 +16.5% | 9.8% | €33.54 | €23.27 | n/a | 8 |
| Jan ’25 | €23.60 | €27.70 +17.4% | 9.8% | €33.51 | €23.25 | n/a | 8 |
| Dec ’24 | €24.80 | €29.67 +19.6% | 7.0% | €34.05 | €26.56 | n/a | 7 |
| Nov ’24 | €25.80 | €29.91 +15.9% | 5.8% | €33.17 | €26.95 | €26.00 | 7 |
| Oct ’24 | €25.80 | €29.30 +13.6% | 8.5% | €33.29 | €24.27 | €27.40 | 8 |
| Sep ’24 | €23.80 | €28.68 +20.5% | 8.3% | €33.22 | €24.22 | €25.20 | 8 |
| Aug ’24 | €24.40 | €28.68 +17.5% | 8.3% | €33.22 | €24.22 | €24.20 | 8 |
| Jul ’24 | €25.60 | €28.68 +12.0% | 8.3% | €33.22 | €24.22 | €23.60 | 8 |
| Jun ’24 | €23.60 | €27.76 +17.6% | 9.2% | €32.80 | €23.23 | €21.20 | 8 |
| May ’24 | €24.20 | €27.76 +14.7% | 9.2% | €32.80 | €23.23 | €21.80 | 8 |
| Apr ’24 | €24.20 | €27.60 +14.1% | 8.7% | €32.49 | €23.02 | €22.40 | 9 |
| Mar ’24 | €24.80 | €28.86 +16.4% | 8.3% | €32.88 | €24.66 | €23.20 | 8 |
| Feb ’24 | €26.20 | €28.86 +10.1% | 8.3% | €32.88 | €24.66 | €23.80 | 8 |
| Jan ’24 | €24.40 | €29.01 +18.9% | 7.9% | €33.07 | €24.80 | €23.60 | 9 |
| Dec ’23 | €26.00 | €30.06 +15.6% | 8.3% | €33.95 | €26.17 | €24.80 | 9 |
| Nov ’23 | €25.80 | €32.57 +26.2% | 8.8% | €37.17 | €27.50 | €25.80 | 8 |
Analyst Forecast: Target price is less than 20% higher than the current share price.